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Abstract
Important regulatory roles of long non-coding RNAs (lncRNAs) have been recently found, and reported as useful biomark-
ers in cancer. To identify a potential expression of the new discovered lncRNA (ARA ), during promotes cell proliferation, 
apoptosis inhibit, migration and cell cycle arrest, we firstly evaluate its expression in two cancer tissues (breast cancer and 
liver cancer) and then compared its variability expression in tumor versus non-tumor samples. Expression profile of ARA 
lncRNA was evaluated using qRT-PCR in paired tumor and marginal non-tumor samples collected from patients who had 
been referred to the Shiraz General. After RNA extraction from tissue samples, cDNA synthesis and RT-qPCR method 
were performed according to the protocols. ARA lncRNA expression level was calculated using  2−ΔΔCt method. Principal-
component analysis followed by receiver operating characteristic curve analyses was performed to evaluate the diagnostic 
potential of selected lncRNA. Our data revealed a significant upregulation (P < 0.001) of ARA in breast and liver tumor 
tissues, in comparison to same patients non-tumor marginal samples. Also, there was a significant difference between the 
expression of ARA lncRNA in breast cancer and liver cancer patients (P < 0.05). In conclusion, the results of our study sug-
gest a possible role of ARA lncRNA in proliferation of breast and liver tissues, as well as its potential usefulness as a novel 
diagnostic biomarker for breast and liver tumors.
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Introduction
Cancer is a major public health problem and one of the 
leading causes of death worldwide. Different cancer types 
have been influenced by some important factors such as 
age, gender, race, environmental factors, diet, and genet-
ics [1]. Today breast cancer, the most common malignity, 
is a significant challenge to human health which causes 
females death (estimated 40,160 deaths in 2017, USA) all 
over the world and has expanded over the past 30 years 
[2–4]. Breast cancer which is a multi-stage process charac-
terized by changing genetic and epigenetic and also affect 
the growth and development in main cellular pathways [5]. 
Several epigenetic changes and genomic polymorphisms in 
genes controlling the circadian rhythm have been shown to 
be significantly associated with cancer development. The 
incidence of liver cancer worldwide is different. There are 
major risk factors for liver cancer including, infection with 
HBV and HCV (hepatitis B and C virus), exposed to cer-
tain chemicals, intake of alcohol and metabolic diseases 
e.g. obesity and diabetes [6, 7]. There are two histological 
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types of liver cancer, hepatocellular carcinoma (HCC, 
one of the most deadly cancers worldwide, derived from 
hepatocytes) and cholangiocarcinoma (derived from the 
intrahepatic bile ducts epithelial lining) [8, 9].
Indeed, the interference between protein-coding genes 
and noncoding RNAs (ncRNAs) is necessary in the 
molecular network that regulates development and dis-
eases [10]. NcRNAs can be classified by their size, such 
as short ncRNAs, midsize ncRNAs and long noncoding 
RNAs (lncRNAs) (19–31, ∼ 20–200 and > 200 nucleo-
tides, respectively). The functional importance of lncR-
NAs in mammalian development and diseases was rec-
ognized and systematic functional and genomic studies 
showed that lncRNAs dysregulation has been associated 
with cancer development [11, 12]. Jiang et al. [13], per-
formed a microarray analysis of lncRNA in adriamycin 
resistant MCF-7/ADR breast cancer cells in comparison 
with parental MCF-7 cells and a lncRNA was validated 
with specific differentially expressed that called lncRNA-
ARA (adriamycin resistance associated).
ARA lncRNA is derived from an intron of p21-activated 
kinase 3 (PAK3) gene at chromosome Xq23 and playing 
a role in promotes cell proliferation, migration, apoptosis 
inhibition and cell cycle arrest [13, 14].
Recently, molecular techniques, especially gene expres-
sion profiling, have been used increasingly, in order to, bio-
marker-based prediction and prognosis, understanding the 
molecular mechanisms, therapeutic strategy development 
and eventual improvement of patient outcomes. Therefore, 
the aim of this study was to evaluate ARA lncRNA expres-
sion by a quantitative reverse transcription PCR (qRT-PCR) 
in breast and liver cancer tissues, to explore its clinical sig-
nificance and to assess the potential value of ARA lncRNA 
as a prognostic marker.
Materials and methods
Cancer sample collection
15 breast cancer samples and 15 liver cancer samples plus 
15 normal tissues of each cancer were received from patients 
referring to Shiraz and Isfahan General Hospitals. Samples 
were obtained from patients undergoing hysterectomy with-
out preoperative chemotherapy or radiotherapy, and were 
histologically evaluated for type and grade. All samples were 
transferred to RNAlater immediately after resection and 
stored at − 20 °C until used for RNA extraction. Informed 
consents were obtained and the experimental procedure 
was approved by the Human Studies Committee of Islamic 
Azad University, Shahrekord Branch, Shahrekord, Iran with 
17621105 approval number.
RNA extraction and cDNA synthesis
Total RNA was extracted from tissue samples using the 
 RNXTM-Plus solution (SinaClon, IRAN) according to the 
manufacturer’s instructions, except for an extended 1-h 
treatment with DNaseI. For checking RNA purity, concen-
tration and integrity, Thermo Scientific NanoDrop™ 1000 
Spectrophotometer and electrophoresd on 2% agarose gel 
were used respectively. One microgram of RNA was used 
for complementary DNA (cDNA) synthesis by using ran-
dom hexamer priming and  PrimeScriptTM-RT reagent kit 
(TaKaRa, Japan) and its concentration was then checked 
spectrophotometrically.
Quantitative real time PCR
All samples were carried out on a rotor gene 6000 
Corbett detection system and quantified qPCR using 
SYBR®Premix Ex Taq™ II kit (TaKaRa, Japan) accord-
ing to the manufacturer’s instructions. Thermal cycling 
conditions were an initial activation step for 5 min at 
95 °C followed by 40 cycles at 95 °C for 15 s and 60 °C 
for 1 min. No template control (NTC) consisting of  H2O 
was included in each run. To verify specificity of PCR 
products, melting curve analysis was performed. Besides, 
PCR products were electrophoresed on 2% agarose gel to 
verify product sizes and specificity. For qPCR analysis, 
all samples were normalized to GAPDH. Forward and 
reverse primers sequences are as follows, respectively: 
ARA -F: 5′-TGC TGC ACT TGA GCA TTA GG-3′ and ARA 
-R: 5′-GCC TCC ATG AAA AAG GAT CA-3′ and GAPDH-
F: 5′-GAA GGT GAA GGT CGG AGT C-3′ and GAPDH-R: 
5′-GAA GAT GGT GAT GGG ATT C-3′. The mean value in 
each triplicate was used to calculate relative lncRNA con-
centration (ΔCt = Ct mean lncRNA-Ct mean GAPDH). 
Expression fold changes were calculated using  2−ΔΔCt 
methods [15]. The qPCR assays were performed in trip-
licate and the data were presented as the mean ± standard 
error of the mean (SEM).
Statistical analysis
The statistical analysis was performed by the GraphPad 
Prism version 7.00 (GraphPad Software, La Jolla Califor-
nia USA). Student’s t test was conducted to compare ARA 
lncRNA expression in clinical samples. The Chi square 
test or Fisher’s exact test was appropriately used for test-
ing the relationship between categorical variables of breast 
and liver cancer. The level of statistical significance was 
set at P < 0.05.
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Results
Expression of ARA lncRNA in patients’ samples
Expression of ARA lncRNA was detectable in breast can-
cer and liver patients compared with healthy subjects. The 
expression of ARA lncRNA was measured in four groups: 15 
healthy subject individuals from the breast cancer and liver 
community, 15 breast cancer patients and 15 liver patients 
by quantitate in patients with breast cancer and liver com-
pared with healthy subjects. A significant over-expression of 
ARA lncRNA had been observed in both of breast and liver 
cancer compared with healthy groups (P < 0.001; Fig. 1). 
As present in Fig. 1, also there is a significant difference 
between the expression of ARA lncRNA in breast cancer 
versus expression of ARA lncRNA in liver cancer patients 
(P value < 0.05).
Correlations between ARA lncRNA expression 
and clinical characteristics
Correlations between clinical characteristics and ARA 
lncRNA expression evaluated by using the Chi square test 
and Fisher’s exact test. Based on the median value of the 
ARA lncRNA expression in breast and liver cancer tis-
sues, the patients were divided into two groups: cases with 
low ARA lncRNA expression and cases with high ARA 
lncRNA expression. High expression levels were classified 
as those that were above the median, while low expression 
levels were below the median. Table 1 indicated the rela-
tionships between ARA lncRNA expression and the clinic 
pathological characteristics of Iranian patients with BC. 
The Chi square test and Fisher’s exact test showed that 
there was a significant correlation between ARA lncRNA 
expression and preneural invasion (P = 0.044). There were 
no significant associations between ARA lncRNA expres-
sion and other patients’ clinic pathological characteristics 
(P > 0.05). Our results indicated that there were no sig-
nificant correlation between ARA lncRNA expression and 
patients’ clinic pathological characteristics in liver cancer 
patients (P > 0.05) (Table 2).Fig. 1  Relative expression of ARA lncRNA in breast and liver cancer cases. Expression levels of the gene was evaluated by qPCR and com-
pared to healthy subjects by ΔΔCt method. The numbers on Y-axis 
show fold changes and the star on the bars indicate significant change
Table 1  Correlation between ARA lncRNA expression and clinic 
pathological variables of breast cancer cases
Variables Cases (%) ARA lncRNA P value
Low High
Age 46.80 ± 2.57 (32–65) 0.447
 ≤ 47 53.3 33.3 20
 > 47 46.7 20 26.7
Tumor grade 0.310
 I 6.7 6.7 0
 II 66.7 40 26.7
 III 26.7 6.7 20
Nuclear grade 0.656
 Low 7.1 7.1 0
 High and intermediate 28.6 14.3 14.3
 High 64.3 35.7 28.6
Tumor stage 0.517
 T1 40 13.3 26.7
 T2 13.3 6.7 6.7
 T3 40 26.7 13.3
 T4 6.7 6.7 0
Tumor size (cm) 0.185
 < 2 73.3 46.7 26.7
 ≥ 2 26.7 6.7 20
Area of invasive component 
4.09 ± 0.13 (0.7–9.5 cm2)
0.714
 < 4 66.7 33.3 33.3
 ≥ 4 33.3 20 13.3
Tumor side 0.447
 Right 53.3 33.3 20
 Left 46.7 20 26.7
Margin 0.876
 Free 73.3 40 33.3
 Involved 26.7 13.3 13.3
Prevascular invasion 0.170
 Negative 26.7 6.7 20
 Positive 73.3 46.7 26.7
Preneural invasion 0.044
 Negative 20 0 20
 Positive 80 53.3 26.7
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Breast cancer‑specific tumor marker
Receiver operating characteristic (ROC) curves were cre-
ated and the area under the curve (AUC) was calculated 
to determine the ability of ARA lncRNA to differentiate 
between cancer cases and controls, by computation sen-
sitivity and specificity for possible cutoff point of ARA 
lncRNA. ROC analysis determined the optimal cutoff 
value for ARA lncRNA to differentiate Breast cancer cases 
from controls. The sensitivity of circulating ARA lncRNA 
were specified to be 100% at the specificity of 100% with 
an area under the ROC curve of 1 (Fig. 2). In Fig. 2 also 
we indicated ROC curve for ARA lncRNA to differenti-
ate liver cases from controls. We found the sensitivity of 
circulating ARA lncRNA: 100% at the specificity of 100% 
with an area under the ROC curve of 1.
Correlation between ARA lncRNA expression 
and patient survival
Association between the expression levels of ARA lncRNA 
with survival investigated through Kaplan–Meier analysis 
in order to assess the prognostic value of ARA lncRNA as 
biomarker for breast and liver cancer. We used the log-rank 
test in breast and liver cancer patients. The Cox proportional 
hazards regression model was also utilized to evaluate the 
predictive value of ARA lncRNA levels in breast and liver 
cancer patients. Overall survival (OS) was defined as the 
time between the date of surgery and date of death or last 
follow-up. Clinicopathological factors and overall survival 
were then analyzed in the high and low ARA lncRNA expres-
sion groups, but no significant differences were observed 
between groups in both breast and liver cancer (P > 0.05, 
Tables 3, 4; Fig. 3).
Discussion
In last decade, various reports have identified different lncR-
NAs with important regulatory parts in cancer initiation and 
progression [16–18]. Non-coding RNAs play critical roles in 
some aspect of cell biology [19, 20]. These molecules, such 
as mRNAs, produced by RNA polymerase II enzyme, cap-
ping process and polyadenylation [21]. In general, lncRNAs 
is contain about 80% of non-coding RNAs [22]. LncRNAs 
can act as oncogenes and tumor suppressor genes, so has 
shown research, which these molecules play an important 
role in oncogenes, angiogenesis, proliferation, migration, 
apoptosis and differentiation, or lncRNAs, greatly affect the 
malignant behavior of cancer [23].
Few systematic studies have focused on global regulation 
of lncRNAs in adriamycin-resistant cells [13]. Adriamycin 
known as a drug for chemotherapy that acts as a target for 
topoisomerase II poison. It is used to treat numerous types 
of cancer e.g. breast and liver cancer [24]. However, adria-
mycin resistance, making the cancer harder to treat. Jiang 
et al. [13] recently recognized several lncRNAs including 
Table 2  Correlation between ARA lncRNA expression and clinic 
pathological variables of liver cancer
Variables Cases (%) ARA lncRNA P value
Low High
Age 55 ± 8.54 (47–74) 0.398
 ≤ 55 60 26.7 33.3
 > 55 40 26.7 13.3
Sex 0.876
 Male 73.3 40 33.3
 Female 26.7 13.3 13.3
Tumor size (cm) 0.782
 < 3 46.7 26.7 20
 ≥ 3 53.3 26.7 26.7
Angioinvasion 0.714
 Yes 33.3 20 13.3
 No 66.7 33.3 33.3
Differentiation 0.535
 Poor differentiated 33.3 13.3 20
 Moderate differentiated 60 33.3 26.7
 Well differentiated 6.7 6.7 0
Fig. 2  Receiver-operating char-
acteristic (ROC) curve analyses 
of ARA lncRNA signature to 
discriminate breast and liver 
cancer patients from normal 
controls
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ARA lncRNA that showed various expression in adriamy-
cin resistant breast and liver cancer cell lines. Over expres-
sion of ARA lncRNA has been found in adriamycin resistant 
MCF7 cells compared to the parental cell line. Breast cancer 
cell lines treatment with adriamycin led to an increase in 
ARA lncRNA expression. ARA lncRNA might be involved in 
self-sufficiency in estrogen signaling. Adriamycin resistant 
breast cancer cell lines restored inhibiting cellular prolifera-
tion and inducing apoptosis. ARA lncRNA may contribute a 
proliferative and survival advantage to adriamycin resistant 
cells [13].
Considering the reports of lncRNAs and cancer, in pre-
sent study we aimed to explore ARA lncRNA expression in 
both breast and liver tumors. ARA lncRNA was reported to 
be upregulated in breast and liver cell lines [13]. The find-
ings of our study revealed this upregulation in both breast 
and liver tissue samples. To the best of our knowledge, 
this is the first report to determine the expression of ARA 
lncRNA in breast and liver cancer in Iran. Nevertheless, 
these findings are preliminary and need to be validated in 
a larger population. Therefore, we could better analyze the 
suitability of ANCR as a potential diagnostic and prognos-
tic biomarker with employing more samples, subdivided 
in different grades and stages of malignancies.
In Conclusion, we demonstrate the expression pattern 
of ARA lncRNA in both breast and liver tumors. LncRNAs 
and profiles based on lncRNAs may also become helpful in 
cancer gene therapy. Our data is the first report on different 
expression of ARA lncRNA in breast and liver cancers in 
IRAN, demonstrating a possible link between the expres-
sion level of ARA lncRNA and cell proliferation. Moreo-
ver, with further validation, ARA lncRNA can potentially 
be considered as a novel tumor biomarker with potential 
diagnostic, prognostic and therapeutic value. However, to 
Table 3  Log rank test for all 
patients undergoing breast 
cancer
Variables Overall survival
HR 95% CI P
ARA (low vs. high) 0.520 0.1059–2.601 0.354
Age (≥ 47 vs. ≥ 47) 1.749 0.3501–8.657 0.506
Tumor grade (Ι–ΙΙΙ vs. ΙΙΙ) 0.560 0.07296–3.501 0.493
Nuclear grade (low vs. high and intermediate-high) 1.977 0.1596–40.67 0.517
Tumor stage (T1–T2 vs. T3–T4) 0.5745 0.1041–2.891 0.800
Tumor size (< 2 cm vs. ≥ 2 cm) 0.460 0.04656–2.841 0.347
Area of invasive component (< 4 cm2 vs. ≥ 4 cm2) 0.576 0.07625–3.827 0.378
Tumor side (right vs. left) 0.585 0.1185–2.937 0.525
Margin (free vs. involved) 0.507 0.05886–3.166 0.416
Prevascular invasion (negative vs. positive) 1.605 0.3264–8.170 0.566
Preneural invasion (negative vs. positive) 0.336 0.01890–1.809 0.166
Table 4  Log rank test for all patients undergoing liver cancer
Variables Overall survival
HR 95% CI P
ARA (low vs. high) 1.702 0.3887–7.950 0.361
Age (≥ 55 vs. ≥ 55) 0.321 0.05506–1.105 0.106
Sex (male vs. female) 0.366 0.04357–1.604 0.159
Tumor size (< 3 cm vs. ≥ 3 cm) 0.370 0.08635–2.124 0.319
Angioinvasion (yes vs. no) 1.003 0.1945–5.180 0.997
Differentiation (poor vs. moder-
ate and well)
0.505 0.1005–1.985 0.347
Fig. 3  Kaplan–Meier survival 
curves for associations of ARA 
with survival. ARA expression 
and overall survival (OS) in 
breast and liver cancer patients: 
ARA low versus high, P > 0.05 
(log-rank test)
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validate our findings, studies on various ethnic groups in a 
larger part of population may warranted the results.
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